KeyLargo: Pembrolizumab + Oxaliplatin + Capecitabine in Gastric Cancer

NCT03342937 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Gastric Cancer
Esophagus Cancer

Interventions

DRUG: Oxaliplatin+Capecitabine+Pembrolizumab

Sponsor

Duke University

Collaborators

[object Object]